Illumina, Inc.
—- Market cap
- —
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ILMN stock price vs BRKR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BRKR's multiple
Needs BRKR P/E.
Implied fair value · at ILMN's multiple
Needs Annual EPS is negative, ILMN P/E.
Snapshot Sep 11, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ILLUMINA, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BRUKER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
THERMO FISHER SCIENTIFIC INC.
ILMN vs TMO
AGILENT TECHNOLOGIES, INC.
ILMN vs A
DANAHER CORP /DE/
ILMN vs DHR
BIO-RAD LABORATORIES, INC.
ILMN vs BIO
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
ILMN vs PACB
Natera, Inc.
ILMN vs NTRA
WATERS CORP /DE/
ILMN vs WAT
BIO-TECHNE Corp
ILMN vs TECH
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ILMN can re-accelerate growth while sustaining its current margin and ROIC profile, then hold or accumulate on weakness because the fundamentals justify a premium to BRKR despite the valuation gap; if growth remains negative and the stock stays above the DCF range, then valuation risk is elevated.
The valuation gap is large on the provided P/S framework: ILMN at $205.10 versus an implied $79.06 suggests 61.5% downside versus BRKR-based estimate. That gap is driven by ILMN’s much stronger profitability profile than BRKR, but the stock still sits well above both BRKR-implied range and the DCF range.
Supporting Metrics